Home  /  Departments  /  DEPARTMENT OF RADIOISOTOPIC DIAGNOSTIC LABORATORY

DEPARTMENT OF RADIOISOTOPIC DIAGNOSTIC LABORATORY

DEPARTMENT OF RADIOISOTOPIC DIAGNOSTIC LABORATORY

Новый рисунок

HEAD OF NUCLEAR MEDICINE DEPARTMENT Rasulova Nigora Valievna, PhD, member of EANM, WARMTH, member of editorial board of World Journal of Nuclear Medicine, and Eurasian Journal of Angiosurgery and Interventional Radiology.


email:niga_r@mail.ru.

Contact address: “Republic Specialized Center of Surgery”, street Farkhadskaya 10,

phone:+99871 2772651

email address^niga_r@mail.ru

 

 Nuclear medicine examinations 2000 per year, radionuclide therapy of bone metastases by Sm-153 oxabifore - 300 patients per year 


Department capacity is 8 beds

Новый рисунок (1)

 Most actual Nuclear Medicine fields of department are:

- Nuclear Cardiology (myocardial perfusion scintigraphy at rest and stress – estimation of ischemia (severity and extension), with nitroglycerine – estimation of viable myocardial tissue, also monitoring and assessment the results of therapy after revascularization.
- Nuclear Nephrourology- functional imaging of kidneys, congenital kidney’s abnormalities, estimation of transplanted kidney’s function.
- Nuclear Oncology – diagnostic with tumor-seeking radiopharmaceutical, WB bone scan, palliative therapy of bone metastases.
- Routine methods: hepatoscintigraphy, indirect lymphoscintigraphy, esophagoscintigraphy, scintigraphy of thyroid gland, scintigraphy of parathyroid glands, MUGA

 

 


FUNCTION OF TRANSPLATED KIDNEY IN A MONTH AFTER OPERATION

Новый рисунок (2)

Новый рисунок (3)

 

MYOCARDIAL PERFUSION SCINTIGRAPHY IN PATIETN WITH ISCHEMIC HEART DISEASE (TRIPL-VESSEL CORONARY ARTERY DISEASE) AFTER REVASCULARIZATION.

MYOCARDIAL PERFUSION AT STRESS AND REST WIHTOUT PERFUSION ABNORMALITIES

Новый рисунок (4)

 

 MALIGNANT METASTATIC LYMPH NODULE IN PATIETN WITH MELANOMA

Новый рисунок (5)

Новый рисунок (6)

  

 

 

 

 

 

 

 

 

  RESULT OF COMBINED THERAPY OF BONE METASTSES BY SM-153 OXABIFORE IN PROSTATE CANCER PATIENT AND SEVERE PAIN SYNDROM. SIGNIFICANT REDUCTION OF PAIN SYNDROM IN 8 DAYS AFTER THERAPY, SIGNIFICANT REDUCTION OF THE METASTSTIC LESIONS IN 4 YEARS AFTER THERAPY, ABSENCE OF THE PAIN SYNDROM.

Новый рисунок (8)